APA (7th ed.) Citation
(2026). Correction: The disruptor of telomeric silencing 1-like (DOT1L) promotes peritoneal fibrosis through the upregulation and activation of protein tyrosine kinases. Molecular Biomedicine.
Chicago Style (17th ed.) Citation
"Correction: The Disruptor of Telomeric Silencing 1-like (DOT1L) Promotes Peritoneal Fibrosis Through the Upregulation and Activation of Protein Tyrosine Kinases." Molecular Biomedicine 2026.
MLA (9th ed.) Citation
"Correction: The Disruptor of Telomeric Silencing 1-like (DOT1L) Promotes Peritoneal Fibrosis Through the Upregulation and Activation of Protein Tyrosine Kinases." Molecular Biomedicine, 2026.
Warning: These citations may not always be 100% accurate.